Aaron Gerds, MD discusses the results of a phase II BELIEVE study of luspatercept as treatment of patients with myelofibrosis-associated anemia.
Aaron Gerds, MD, assistant professor of Medicine, Cleveland Clinic - Taussig Cancer Center, discussed the results of a phase II BELIEVE study of luspatercept (Reblozyl) as treatment of patients with myelofibrosis-associated anemia.
Every cohort in the study had responses to treatment with luspatercept. Additionally, luspatercept successfully reduced the transfusion burden in 21.4% of the study subjects compared only 4.5% of those who received placebo, meeting the primary end point of the study.
Gerd notes, however, that responses were higher in patients who received ruxolitinib (Jakafi) along with the luspatercept.
<< View more content from the 2019 American Society of Hematology Annual Meeting
Connecting Spleen Volume Reduction to Survival Outcomes in MF
April 21st 2024During a Case-Based Roundtable® event, Raajit K. Rampal, MD, PhD, discussed the correlation between spleen volume responses and survival outcomes for patients with myelofibrosis in the second article of a 2-part series.
Read More
Savona Discusses First-Line JAK Inhibition for Patients With Myelofibrosis at Risk of Anemia
April 17th 2024During a Case-Based Roundtable® event, Michael Savona, MD, and participants discussed the case of a patient with myelofibrosis and moderate anemia receiving JAK inhibitor therapy.
Read More